| |
|
Non-aqueous silicone elastomer gels as a
vaginal microbicide delivery system for the HIV-1 entry inhibitor
maraviroc.
Forbes CJ, Lowry D, Geer L,
et
al
J Control Release.
2011 Aug 12.
Abstract
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist
maraviroc on chemotactic activity of monocytes,
macrophages and dendritic cells.
Rossi R, Lichtner M, De Rosa A,
et al
Clin Exp Immunol. 2011
Nov;166(2):184-90.
Abstract
Allosteric Model of Maraviroc Binding to CC Chemokine
Receptor 5 (CCR5).
Garcia-Perez J, Rueda P, Alcami J,
et
al
J Biol Chem.
2011 Sep 23;286(38):33409-21.
Abstract
Lessons from maraviroc clinical trials.
Troia-Cancio P, Asmuth DM.
Expert Rev Anti Infect Ther.
2011 Jun;9(6):649-51
Abstract
Pharmacological Modulation of Chemokine Receptor
Function.
Scholten D, Canals M, Maussang D, et al
B
r J Pharmacol.
2011 Jun 23
Abstract
HIV-1 Dual/Mixed Tropic Isolates Show Different Genetic and Phenotypic
Characteristics
and Response to Maraviroc In Vitro.
Svicher V, Balestra E, Cento V, et al
Antiviral Res.
2011 Feb 21.
Abstract
HIV-1 escape from the CCR5 antagonist maraviroc associated with an
altered and less efficient mechanism
of gp120-CCR5 engagement that attenuates macrophage-tropism.
Roche M, Jakobsen MR, Sterjovski J,
J Virol. 2011 Feb
23.
Abstract
FULL-TEXT ARTICLE
Deep
sequencing to infer HIV-1 co-receptor usage: application to three
clinical trials of maraviroc in treatment-experienced patients.
Swenson LC, Mo T, Dong WW,
et
al
J Infect Dis.
2011 Jan 15;203(2):237-45
Paper
FULL-TEXT ARTICLE
Comparison of phenotypic and genotypic tropism determination in
triple-class-experienced HIV patients
eligible for maraviroc treatment.
Vandekerckhove L, Verhofstede C, Demecheleer E, et al
J Antimicrob Chemother.
2010 Dec 31
Paper
FULL-TEXT ARTICLE
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and
maraviroc protects against HIV-1 vaginal transmission
in a humanized mouse model.
Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R.
PLoS One. 2010 Dec
21;5(12):e15257
Paper
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma
concentrations are influenced by SLCO1B1 521 T>C
polymorphism.
Siccardi M, D'Avolio A, Nozza S, et al
Pharmacogenet Genomics.
2010 Dec;20(12):759-65.
Abstract
Maraviroc does not affect humoral response to the pandemic influenza
A-H1N1v 2009
adjuvanted vaccine in HIV-1-infected patients.
Canestri A, Krivine A, Assoumou L, et al
AIDS. 2010
Oct 19
Abstract |
A WEEK-IN REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and
Inflammation
and Associations with CD4 Cell Rises in HIV-Infected Patients.
Funderburg N, Kalinowska M, Eason J, et al
PLoS One. 2010 Oct 6;5(10). pii:
e13188.
Paper |
Hepatic safety and tolerability in the maraviroc
clinical development program.
Ayoub A, Alston S, Goodrich J, et al
AIDS. 2010
Oct 7.
Abstract |
Anti-Inflammatory Effect of Maraviroc in an HIV-Infected Patient With
Concomitant Myositis:
A Case Report.
Capetti AF, Pocaterra D, Zucchi P
J
Int Assoc Physicians AIDS Care 2010 Jul-Aug;9(4):201-2.|
Abstract |
Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected
Patients.
Tiraboschi JM, Niubo J, Curto J, Podzamczer D.
J Acquir Immune Defic Syndr.
2010 Aug 11
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc: a review of its use in the management of
CCR5-tropic HIV-1 infection.
Perry CM.
Drugs.
2010
Jun 18;70(9):1189-213
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
When and how to use maraviroc in HIV-infected patients.
Soriano V, Perno CF, Kaiser R, et al
AIDS. 2009 Oct 14
Abstract |
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of
HIV-Negative
Women.
Dumond JB, Patterson KB, Pecha AL, et al
J Acquir Immune Defic Syndr. 2009 Jun 19
Abstract
|
A Double-Blind, Placebo-Controlled Trial of Maraviroc in
Treatment-Experienced Patients Infected with
Non-R5 HIV-1.
Saag M, Goodrich J, Fätkenheuer
G, Clotet B,
et al
J Infect Dis.
2009 Jun 1;199(11):1638-1647
Abstract |
Maraviroc: A coreceptor CCR5 antagonist for management of HIV
infection.
Yost R, Pasquale TR, Sahloff EG.
Am J Health Syst Pharm.
2009 Apr 15;66(8):715-26
Abstract
|
Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human
Immunodeficiency
Virus Type 1.
Hunt JS, Romanelli F.
Pharmacotherapy.
2009 Mar;29(3):295-304
Abstract
|
Maraviroc: integration of a new antiretroviral drug class into clinical
practice.
Vandekerckhove L, Verhofstede C, Vogelaers D.
J Antimicrob Chemother. 2008
Apr 9
Abstract
A WEEK IN REVIEW FEATURED REPORT
Effect of single doses of maraviroc on the QT/QTc interval in healthy
subjects.
Davis JD, Hackman F, Layton G, et al
Br
J Clin Pharmacol. 2008 Apr;65 Suppl 1:68-75
New approaches in the treatment of HIV/AIDS - focus on maraviroc and
other CCR5 antagonists.
Schlecht HP, Schellhorn S, Dezube BJ, Jacobson JM.
Ther Clin Risk Manag. 2008 Apr;4(2):473-85.
Abstract
|
A receptor theory-based semimechanistic PD model for the CCR5
noncompetitive antagonist
maraviroc.
Jacqmin P, McFadyen L, Wade JR.
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:95-106.
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc.
Fadel H, Temesgen Z.
Drugs Today (Barc). 2007 Nov;43(11):749-58.
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency
virus (HIV)-1.
Ndegwa S.
Issues Emerg Health Technol. 2007 Dec;(110):1-8.
Abstract
|
Maraviroc, a chemokine CCR5 receptor antagonist for the
treatment of HIV infection
and AIDS.
Meanwell NA, Kadow JF.
Curr Opin Investig Drugs.
2007 Aug;8(8):669-81.
Abstract
|
Access denied? The status of co-receptor inhibition to counter
HIV entry.
Biswas P, Tambussi G, Lazzarin A
Expert Opin Pharmacother. 2007 May;8(7):923-33.
Abstract
|
Assessing theoretical risk and benefit suggested by genetic association
studies of CCR5:
experience in a drug development programme for maraviroc.
Wheeler J, McHale M, Jackson V, Penny M.
Antivir Ther. 2007;12(2):233-45.
Abstract
|
FULL TEXT
ARTICLE
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1)
variants in a minority
of HIV-1-infected patients following treatment with the CCR5
antagonist maraviroc is from a
pretreatment CXCR4-using virus reservoir.
Westby M, Lewis M, Whitcomb J, et al
J Virol. 2006
May;80(10):4909-20.
Paper
|
FULL TEXT ARTICLE
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective
small-molecule inhibitor of
chemokine receptor CCR5 with broad-spectrum anti-human
immunodeficiency virus type 1 activity.
Dorr P, Westby M, Dobbs S, et al
Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32.
Paper
|
| |
Pharmacokinetic Effects of Co-Administration of Lersivirine with Raltegravir or
Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011 Nov 28
Abstract
Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and
Rectal Tissue of
Healthy HIV-negative Men.
Brown KC, Patterson KB, Malone SA,
et
al
J Infect Dis.
2011 May;203(10):1484-90
Abstract
The use of the SAEM algorithm in MONOLIX software for estimation of
population pharmacokinetic-pharmacodynamic-viral
dynamics parameters
of maraviroc in asymptomatic HIV subjects.
Chan PL, Jacqmin P, Lavielle M,
et al
J Pharmacokinet Pharmacodyn.
2010 Nov 19
Abstract |
A WEEK-IN REVIEW FEATURED REPORT
Assessment of the pharmacokinetics of co-administered
maraviroc and raltegravir.
Andrews E, Glue P, Fang J,
et al
Br J Clin Pharmacol.
2010 Jan;69(1):51-57.
Abstract |
Pharmacokinetics, safety and tolerability of a single oral
dose of maraviroc in HIV-negative
subjects with mild and moderate hepatic impairment.
Abel S, Davis JD, Ridgway CE, et al
Antivir Ther.
2009;14(6):831-7
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc: pharmacokinetics and drug interactions.
Abel S, Back DJ, Vourvahis M.
Antivir Ther.
2009;14(5):607-18.
Abstract
|
A pharmacokinetic-pharmacodynamic model to optimize the phase
IIa development program of
maraviroc.
Rosario MC, Poland B, Sullivan J, et al
J Acquir Immune Defic Syndr. 2006 Jun;42(2):183-91.
Abstract |
| |
|
A WEEK-IN-REVIEW FEATURED REPORT
Deep V3 sequencing for HIV type 1 tropism in treatment-naive
patients: a reanalysis of the MERIT trial of maraviroc.
Swenson LC, Mo T, Dong WW, et al
Clin Infect Dis. 2011 Oct;53(7):732-42.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Clinical Utility of Maraviroc.
Parra J, Portilla J, Pulido F,
et al
Clin Drug Investig. 2011
May 20.
Abstract
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in
primary cells: implications for treatment and prevention.
Latinovic O, Le N, Reitz M, Pal R,
et al
AIDS. 2011 Jun 1;25(9):1232-5.
Abstract
Use of Maraviroc-, Raltegravir-, and Etravirine-Containing Regimens in
Treatment-Experienced Patients:
A Case-Series Study.
Youngblood C, Sayana S, Khanlou H.
J Int Assoc Physicians AIDS Care (Chic).
2011 Mar 23
Abstract
Maraviroc first-line therapy for HIV infection. Too risky.
[No authors listed]
Prescrire Int. 2010
Nov;19(110):252-4.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Two-Year Safety and Virologic Efficacy of Maraviroc in
Treatment-Experienced Patients
With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis
of MOTIVATE 1 and 2.
Hardy WD, Gulick RM, Mayer H, et al
J Acquir Immune Defic Syndr.
2010 Aug 11.
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Long-Term Immunovirogical Effect And
Tolerability Of A Maraviroc-Containing Regimen
In Routine Clinical Practice.
Genebat M, Ruiz-Mateos E, Pulido I, et al
Curr HIV Res. 2010 Jul 20
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc-containing regimen suppresses HIV replication
in the cerebrospinal fluid of patients
with neurological symptoms.
Melica G, Canestri A, Peytavin G, et al
AIDS.
2010 Jul 1
Abstract
|
Maraviroc versus Efavirenz, Both in Combination with
Zidovudine-Lamivudine, for the Treatment
of Antiretroviral-Naive
Subjects with CCR5-Tropic HIV-1 Infection.
Cooper DA, Heera J, Goodrich J, et al
J Infect Dis.
2010 Feb 12.
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist
Maraviroc.
Latinovic O, Kuruppu J, Davis C,
et al
Clin Med Ther. 2009;1:1497-1510
Abstract |
Impact of adding maraviroc to antiretroviral regimens in patients with full
viral suppression
but impaired CD4 recovery.
Stepanyuk O, Chiang TS, Dever LL, et al
AIDS. 2009 Jul 4
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc efficacy in clinical studies on the
development of the molecule
Moreno S, Hernández B, Gutiérrez C, Delsol E.
Enferm Infecc Microbiol Clin.
2008 Oct;26 Suppl 11:17-22.
Abstract |
A WEEK IN REVIEW FEATURED
REPORT
Maraviroc for previously treated patients with R5 HIV-1
infection.
Gulick RM, Lalezari J, Goodrich J, et al
N Engl J Med. 2008 Oct 2;359(14):1429-41.
Abstract
|
A WEEK IN REVIEW FEATURED
REPORT
Subgroup analyses of maraviroc in previously treated R5 HIV-1
infection.
Fätkenheuer G, Nelson M, Lazzarin A, et al
N Engl J Med. 2008 Oct 2;359(14):1442-55.
Abstract
|
Post-exposure prophylaxis with a maraviroc-containing regimen after
occupational exposure to a
multi-resistant HIV-infected source person.
Méchai F, Quertainmont Y, Sahali S, et al
J Med Virol. 2007 Nov 26;80(1):9-10
Abstract |
Efficacy of short-term monotherapy with maraviroc, a new CCR5
antagonist, in patients infected
with HIV-1.
Fatkenheuer G, Pozniak AL, Johnson MA, et al
Nat Med. 2005 Nov;11(11):1170-2.
Abstract |
| |
Baseline CD4(+) T-cell counts and weighted background susceptibility
scores strongly predict response
to maraviroc regimens in treatment-experienced patients.
Schapiro JM, Boucher CA, Kuritzkes DR, et al
Antivir Ther.
2011;16(3):395-404
Abstract
Discordance rates between Trofile test and short-term virological response to
maraviroc.
Genebat M, Ruiz-Mateos E, González-Serna A, et al
Antiviral Res. 2011
Feb;89(2):182-5.
Abstract
An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857)
in human plasma, urine and cerebrospinal fluid.
Brewer E, Felix T, Clarke P, et al
Biomed Chromatogr.
2010 Dec;24(12):1316-23.
Abstract |
FULL-TEXT PDF ARTICLE
Development and application of a simple LC-MS method for the
determination of plasma
maraviroc concentrations.
Takahashi M, Hirano A, Okubo N, et al
J Med Invest.
2010;57(3,4):245-250.
Paper |
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a
phenotypic assay
and correlation with the virological response to maraviroc: the ANRS
GenoTropism study.
Recordon-Pinson P, Soulié C, Flandre P, et al
Antimicrob Agents Chemother. 2010 Jun 7
Abstract |
A validated high-performance liquid chromatography-ultraviolet method for
quantification
of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
D'Avolio A, Simiele M, Baietto L,
et al
Ther Drug Monit. 2010
Feb;32(1):86-92
Abstract |
Correlation between the Trofile(R) test and virological response to a
short-term maraviroc exposure
in HIV-infected patients.
Genebat M, Ruiz-Mateos E, León JA, et al
J Antimicrob Chemother. 2009 Aug 11.
Abstract |
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral
agents: Raltegravir,
maraviroc, darunavir, and etravirine.
Fayet A, Béguin A, Zanolari B, Cruchon S, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2009 Feb 28
Abstract
|
Simultaneous determination of maraviroc and raltegravir in human
plasma by HPLC-UV.
Notari S, Tommasi C, Nicastri E, et al
IUBMB Life.
2009 Mar 24;61(4):470-475
Abstract
A liquid chromatography-tandem mass spectrometry assay for
quantification of nevirapine, indinavir,
atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz,
tipranavir, darunavir and maraviroc
in the plasma of patients infected with HIV.
Martin J, Deslandes G, Dailly E, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2009 Aug 3
Abstract |
|
|
| |
FULL-TEXT ARTICLE
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and
other CCR5 antagonists in vitro has an inherent, low-level ability
to utilize MVC-bound CCR5 for entry
Roche M, Jakobsen MR, Ellett A,
et al
Retrovirology. 2011
Nov 7;8:89.
Paper
FULL-TEXT
ARTICLE
Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult
Evolution from CCR5 to CXCR4 Coreceptor Use.
Nedellec R, Coetzer M, Lederman MM,
et al
PLoS One.
2011;6(7):e22020.
Paper
A combination of polymorphic mutations in V3 loop of
HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Yuan Y, Maeda Y, Terasawa H,
et al
Virology.
2011 May 10;413(2):293-9.
Abstract
Evaluation of Primary Resistance to HIV Entry Inhibitors Among
Brazilian Patients Failing Reverse
Transcriptase/Protease Inhibitors Treatment Reveal High Prevalence
of Maraviroc Resistance-
Related Mutations.
Alencar CS, Nishiya A, Ferreira S, et al
AIDS Res Hum Retroviruses.
2010 Oct 26.
Abstract |
A maraviroc-resistant HIV-1 with narrow cross-resistance to other
CCR5 antagonists depends
on both N-terminal and extracellular loop domains of drug-bound
CCR5.
Tilton JC, Wilen CB, Didigu CA, et al
J Virol. 2010
Aug 11.
Abstract |
Mechanisms of resistance and failure of treatment
with maraviroc
Delgado R.
Enferm Infecc Microbiol Clin.
2008 Oct;26 Suppl 11:28-33
Abstract
|
|
|
Maraviroc (Selzentry)
Journal Citations |
|
Animal
Studies
Documents
identified with this icon are in Portable Document Format (PDF) and require the